Radiotherapy with Reduced Dose and Volume Using Sentinel Lymph Node Mapping
for Head and Neck Squamous Cell Carcinoma with One-Sided Lymph Node Involvement
Led by Universitaire Ziekenhuizen KU Leuven · Updated on 2024-07-01
147
Participants Needed
10
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating head and neck squamous cell carcinomas HNSCC located in the oral cavity, oropharynx, larynx, or hypopharynx, specifically in patients with positive lymph nodes on only one side of the neck and no distant metastasis. The study focuses on evaluating two strategies the use of sentinel lymph node mapping to customize the areas of the neck to be irradiated and reducing the radiation dose. This research aims to decrease the volume and dose of radiation to the contralateral neck to minimize severe side effects while maintaining cancer control.
Participants will undergo different radiotherapy approaches based on sentinel lymph node mapping results. If the scan shows drainage only on the tumor side and the tumor does not cross the midline, patients will receive radiation on the same side with a reduced dose, sparing the opposite side. If drainage to the opposite side is present, participants will be randomly assigned to either receive radiation to the entire lymph node level containing the sentinel node or only to the sentinel node itself, both at reduced doses. The treatment targets are adapted individually according to the lymph node drainage pattern.
During the study, patients will be monitored for contralateral regional control over two years after radiotherapy. Quality of life questionnaires will be completed regularly during the first two years. Researchers will also assess normal tissue complication probability, local cancer control, overall survival, and radiotherapy-induced toxicity. The study includes imaging assessments and clinical evaluations to measure treatment effects and safety, with follow-up visits scheduled up to two years post-treatment.
CONDITIONS
Brief Title
Dose De-escalation and Sentinel LN Mapping Driven Radiotherapy of Contralateral Neck in Ipsilateral Node Positive HNSCC
Research Team
J
Jean-François Daisne, MD, PhD
C
Chris Bruyninckx, BA
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Written informed consent given according to ICH/GCP and national/local regulations prior to screening.
WHO performance status of 0 or 1.
Age 18 years or older.
Pathologically confirmed invasive head and neck squamous cell carcinoma in the oral cavity, oropharynx (any HPV status), larynx, or hypopharynx.
Treatment plan by multidisciplinary board for radical radiotherapy with or without chemotherapy.
Baseline neck imaging including CT with iodine contrast (≤ 2.5 mm slices), optional MRI, and FDG-PET/CT.
Tumor staging: cT1 (except T1 of glottis) to T4a (or compatible cT4 for p16+ oropharyngeal tumors).
Contralateral neck nodes cN0 by imaging criteria.
Ipsilateral neck nodes positive (cN1, cN2a, cN2b, cN3b or cN1 for p16+ oropharyngeal).
No distant metastasis.
You will not qualify if you...
Prior neck radiotherapy or surgery affecting lymphatic drainage.
Cancer in the last five years except certain skin or cervix conditions.
Absolute contraindication to iodine contrast even after pre-medication.
Head and neck squamous cell carcinoma from nose, sinuses, esophagus, salivary glands or nasopharynx.
Non-squamous cell carcinoma histology.
Positive contralateral neck nodes by size or biopsy.
Synchronous second malignancy.
Distant metastasis.
Tumor crossing midline without contralateral mapping after tracer injection.
Tumor too large for safe injection as judged by surgeon.
Psychological, social, or geographic conditions risking safety or compliance.
Female pregnancy, breastfeeding, or childbearing potential without effective contraception.
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening and enrollment visit (in-person)
Treatment
Duration - Approximately 6 to 7 weeks of radiotherapy treatment
Participants receive tailored radiotherapy based on sentinel lymph node mapping to reduce radiation dose and volume on the contralateral side of the neck, with or without chemotherapy.
Daily visits for radiotherapy sessions over treatment period
Follow-up
Duration - Up to 2 years after radiotherapy
Participants are monitored for contralateral regional control, quality of life, toxicity, and survival outcomes after completing radiotherapy.
Visits every 2 months in the first year and every 3 months in the second year for assessments
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Similar Trials
Comparing 2 versus 3 Courses of Cisplatin Chemotherapy with Radiotherapy After Surgery for High-risk Head and Neck Squamous Cell Carcinoma
Phase 2 Study Evaluating Nivolumab Alone or Combined with 5-Azacytidine Before Surgery
in Treating Resectable HPV-Associated Head and Neck Squamous Cell Cancer
Phase II Trial Comparing Two 5-Fluorouracil Dosing Schedules for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Previously Treated With Platinum and PD-1 Inhibitors
Phase III Study of UCB4594, a Monoclonal Antibody Targeting HLA-G, Alone and With Other Cancer Treatments in Adults With Advanced Solid Tumors
Study of Iparomlimab and Tuvonralimab With or Without Chemotherapy in Adults Aged 18 to 75 With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Study of Amivantamab Alone or with Other Therapies for Head and Neck Squamous Cell Carcinoma
Randomized Study Comparing Amivantamab Plus Pembrolizumab and Carboplatin with Standard Pembrolizumab, 5-Fluorouracil, and Platinum Therapy in Treatment-Naive RecurrentMetastatic Head and Neck Squamous Cell Carcinoma
Study of BMS-986340 Alone and With Nivolumab, Docetaxel, or Pumitamig in Adults With Advanced Solid Tumors
Phase IIIa Study of DM005 Drug Treatment in Adults With Advanced Solid Tumors
MRI and Tumor Microenvironment Biomarker Study in Head and Neck Squamous Cell Carcinoma Tracking Changes During Curative Radiotherapy or Surgery
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Individualized Prophylactic Neck Irradiation in Patients with cN0 Head and Neck Cancer Based on Sentinel Lymph Node(s) Identification: Definitive Results of a Prospective Phase 1-2 Study.
SPECT/CT lymphoscintigraphy of sentinel node(s) for superselective prophylactic irradiation of the neck in cN0 head and neck cancer patients: a prospective phase I feasibility study.